Shots :
- The (AVT03-GL-P01) study assessing safety, PK and tolerability of AVT03 (denosumab) vs Prolia in healthy adult individuals met the 1EPs
- The confirmatory study of AVT03 in patients and a trial to evaluate PK of AVT03 vs Xgeva in healthy adult individuals is ongoing
- AVT03, a mAb, targets RANK ligand to reduce the numbers and function of osteoclast for stopping bone resorption and cancer-induced bone destruction
Ref: Alvotech | Image: Alvotech | Press Release
Related News:- Boan Biotech Highlights Clinical Updates for BA6101 (biosimilar, Prolia) and BA1102 (biosimilar, Xgeva) to Treat Various Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
